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Background: Malignant glioma is one of the most devastating tumors in adults with poor patient prognosis.
Notably, glioma often exhibits resistance to conventional chemotherapeutic approaches, complicating
patient treatments. However, the molecular mediators involved in tumor chemoresistance remain poorly
defined, creating a barrier to the successful management of glioma. In the present study, we hypothesized
that the antioxidant transcription factor, Nrf2 (nuclear factor erythroid-derived 2 like 2), attenuates glioma
cytotoxicity to Carmustine (BCNU), a widely used chemotherapeutic agent known to modulate cellular
oxidative balance.
Methods: To test the hypothesis, we employed human malignant glioma cell line, U87MG and overexpression of
Nrf2 in glioma cells was achieved using both pharmacological and genetic approaches.
Results: Notably, induction of Nrf2 was associated with increased expression of heme oxygenase-1 (HO-1), a stress
inducible enzyme involved in anti-oxidant defense. In addition, over expression of Nrf2 in U87MG cells significantly
attenuated the cytotoxicity of Carmustine as evidenced by both cellular viability assay and flow cytometry analysis.
Consistent with this, antioxidants such as glutathione and N-acetyl cysteine significantly reduced Carmustine
mediated glioma cytotoxicity.
Conclusions: Taken together, these data strongly implicate an unexplored role of Nrf2 in glioma resistance to
Carmustine and raise the possible use of Nrf2 inhibitors as adjunct to Carmustine for the treatment of malignant
glioma.
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Malignant glioma is one of the most devastating tumors
in adults. The worldwide annual incidence of malignant
glioma is approximately 6 cases per 100,000 people [1]
and each year, more than 14,000 new cases are being
diagnosed in the United States. In contrast to other solid
tumors, glioma presents various therapeutic challenges
that include its intracranial location, aggressive bio-
logical behavior and infiltrative growth. Though multi-
modal treatment regiments are being used for the
treatment of malignant glioma, it is often associated with* Correspondence: sramesh@gru.edu
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patients is still less than 14 months [2].
Carmustine or bis-chloroethylnitrosourea (BCNU)
wafer is the only FDA approved intracerebral chemo-
therapeutic agent for the treatment of newly diagnosed
and recurrent malignant glioma [3]. After maximal
surgical resection of tumors, biodegradable wafers of
Carmustine (Gliadel®) are implanted inside the tumor
cavity, providing an innovative way of delivering chemo-
therapy directly to the brain tumors with minimal
systemic toxicity and greater efficacy than systemic
Carmustine administration [4]. However, the recent
studies demonstrated that the efficacy of Carmustine is
substantially limited by chemoresistance [5]. Carmustine
exerts tumor cytotoxicity via multiple mechanisms anded Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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[6,7]. In addition, Carmustine is known to carbamylate ly-
sine residues on proteins [8] causing protein carbamyla-
tion, a post translational protein modification that could
irreversibly inactivate enzymes including glutathione
reductase [9-11]. Therefore, by inhibiting glutathione
reductase an enzyme that plays critical roles in cellular
oxidative balance, Carmustine treatment may modu-
late the cellular oxidative status.
Nrf2 is a key redox-sensitive transcription factor that
regulates the expression of endogenous antioxidants,
phase II detoxification enzymes, and other cellular de-
fensive proteins in response to cellular stress. The tran-
scriptional activity of Nrf2 is negatively regulated by the
cytoplasmic protein, Kelch-like ECH-associated protein
1 (Keap1) [12,13]. Under homeostatic conditions, Keap1
constitutively targets Nrf2 for ubiquitin conjugation and
subsequent proteasome degradation in the cytoplasm by
acting as a substrate adaptor for the Cul3-based E3
ubiquitin ligase complex [14]. Upon exposure of cells
to oxidative stress or Nrf2 inducers such as tert-
butylhydroquinone (TBHQ), multiple cysteine residues
on Keap1 are alkylated, compromising the ability of
Keap1 to efficiently ubiquitinate Nrf2 and resulting in
elevated Nrf2 protein levels and transcriptional activ-
ity. Though recent studies demonstrated a role of Nrf2
in glioma invasion [15], angiogenesis [16,17], the self-
renewal of glioma stem cells [18], and temozolomide-
mediated cytotoxicity [19,20] its precise role in tumor
progression remains largely controversial. Moreover,
the functional role of antioxidant transcription factor
Nrf2 in malignant glioma resistance to Carmustine
remains largely uncharacterized. Altogether, given the
role of Nrf2 in antioxidant defense mechanisms coupled
with the potential modulation of cellular oxidative status
by Carmustine treatment, we hypothesized that Nrf2 may
functionally regulate tumor cell sensitivity to the cytotoxic




All cell culture reagents, sera, and media were purchased
from Hyclone Laboratories (Logan, UT). Carmustine
(BCNU) and tert-butylhydroquinone (TBHQ) were pur-
chased from Sigma-Aldrich Co (St. Louis, USA). TBHQ
was dissolved in dimethyl sulfoxide (DMSO) and DMSO
was used as a vehicle in all studies. MTT was purchased
from Calbiochem (USA).
Cell culture
Human U87MG malignant glioma cells (American
Type Tissue Collection, Manassas, VA) were cultured
in Dulbecco’s modified Eagle’s medium (DMEM)supplemented with 5% fetal bovine serum, 5% bovine
growth serum, and antibiotics in a 37°C humidified in-
cubator at 5% CO2.
Cellular viability assay
MTT reduction assay was performed as an estimate of
cellular viability, as described earlier [21]. Briefly, cells
(3 × 104 cells/well) were plated overnight in 24-well
plates and treated with vehicle or TBHQ or Carmustine
as detailed in respective figure legends. Following treat-
ments, MTT (5 mg/mL; 50 μl/well) was added to each
well and incubated for 4 h at 37°C. The wells were then
emptied and the blue formazan salts were dissolved in
acidic isopropanol (400 μl/well) and absorbance was
measured using a plate reader (Biotek) at 540 nm using
a reference wavelength of 690 nm. Cellular viability was
normalized to vehicle treated control wells, which repre-
sented 100% viability.
BrdU (bromodeoxyuridine) incorporation assay
Cell proliferation was measured by estimating BrdU
incorporation using a Proliferation Assay kit (Calbiochem,
Merk, Darmstadt, Germany), as per the manufacturer’s in-
structions. Briefly, U87MG cells were cultured overnight
in 96-well plates at a density of 104 cells/100 μl/well in
complete growth media and treated with TBHQ/Vehicle
for 24 h. BrdU label solution (Calbiochem) was added 4 h
prior to the completion of TBHQ treatment. The anti-
BrdU antibody was added and incubated for 1 h at room
temperature and this was followed by 30 min incubation
with the respective secondary antibody. The absorbance
was read at 450 nm on a Synergy HT Biotech Elisa reader.
Flow cytometry
Cell death was quantified by flow cytometry, as described
previously by our group [22]. Briefly, the cells were plated
overnight at density of 100,000 cells/well and treated with
either vehicle or TBHQ (30 micromoles) for 6 h. The
wells were then emptied and vehicle or Carmustine
(50 μg/ml) was added and incubated for 18 h. Afterwards,
the adherent and non-adherent cells were collected and
washed and the cell suspensions were stained for 15 min
at room temperature with annexin V-PE (BD Pharmigen,
San Diego, CA), an early apoptotic marker, and with 7-
aminoactinomycin D (7-AAD), a fluorescent marker that
labels dead cells. The percentage of apoptotic or necrotic
cell death was quantified using a FACScan flow cytometry.
Immunocytochemistry
U87MG cells after treatment with either vehicle/TBHQ
(30 μM) for 6 h were fixed with ice cold methanol for
5 minutes. Cellular fixation was followed by washing
twice with PBS and a 10 min treatment with 0.1%
Triton‐X 100 in PBS. Cells were then incubated with
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any nonspecific binding of antibodies. Primary antibody
[Nrf2 (1:100; Santa Cruz Biotechnology, Santa Cruz,
CA)] incubation was carried out for 18 h at 4°C, and this
was followed by secondary antibody (Alexa Fluor) incu-
bation for 2 h at room temperature. Finally, cells were
cover slipped with a mounting medium containing nu-
clear stain DAPI and immunofluorescent analysis was
performed using a LSM510 Meta confocal laser micro-
scope (Carl Zeiss, Thornwood, NY, USA).
Western blotting
Western blotting was performed as described by our
laboratory [21,22]. Briefly, cells after respective treat-
ment were washed with phosphate buffered saline
(PBS) and whole cell lysates were collected in radioim-
munoprecipitation (RIPA) buffer containing protease
inhibitor cocktail, and phenyl methane sulfonyl fluor-
ide (PMSF). Cell lysates were sonicated, centrifuged for
5 min at 14,000 rpm at 4°C, and protein concentrations
were quantified by BCA protein assay kit (Pierce,
Rockford, IL). Thirty micrograms of protein was resolved
on a 4–20% sodium dodecyl sulfate–polyacrylamide gel
and transferred onto a polyvinylidene difluoride (PVDF)
membrane. Blots were incubated overnight at 4°C in
respective primary antibody [Nrf2 (1: 250) Santa Cruz
Biotechnology, Santa Cruz, CA), heme oxygenase-1 (1:
1000; Abcam, Cambridge, MA), or β-actin (1:3000; Sigma,
St Louis, MO)] followed by a 2-h incubation with a
corresponding Alexa Fluor secondary antibody. Blots
were visualized using the Li-Cor Odyssey near-infrared
imaging system and quantified using Quantity One
software (Bio-Rad, Foster City, CA).
Over expression of Nrf2
Precision LentiORF lentiviral particles (Thermo scientific
Open Biosystems) were used to overexpress Nrf2 in
U87MG cells as per manufacturer’s recommended proto-
col. Briefly, U87MG cells were transduced with lentiviral
particles at MOI (Multiplicity of infection) of 1.8. Media
was replaced 72 h later with growth media and after 48 h,
cells were challenged with blasticidin S (5 μg/mL; the
minimum concentration required to kill non-transduced
U87MG cells). Blasticidin S selection continued for
one week, with media replenishment thrice weekly.
The Blasticidin S resistant cells were collected and
Western blotting was performed to ensure stable Nrf2
overexpression. Control cells were stably transduced
with lentiviral particles containing Red Fluorescent
Protein (RFP).
ELISA-based measurement of Nrf2 activity
The TransAM Nrf2 Kit (Active Motif; California, USA)
was used to assay the DNA-binding activity of Nrf2 inthe nuclear extracts of both the RFP and Nrf2-
overexpressed cells. In brief, 5 μg of nuclear extract pre-
pared using nuclear extraction kit (Active Motif, USA)
was incubated in a 96-well plate that was coated with
oligonucleotide containing a consensus binding site for
Nrf2. After 1 h of incubation, the wells were incubated
with 100 μl of a 1:1000 dilution of Nrf2 antibody. This
was followed by incubation with 100 μl of a 1:1000 dilu-
tion of horseradish peroxidase-conjugated secondary
antibody at room temperature. The wells were developed
using 100 μl of developing solution for 10 min before
the addition of 100 μl of stop solution. Optical density
was read at 450 nm with a reference wavelength of
650 nm using a Synergy HT Biotech Elisa reader.
Statistical analysis
For cellular viability studies, n = 4 wells/group were used
within each experiment for analysis. For western blot-
ting, all experiments were performed at least in triplicate
using independent cell cultures. All experiments were
repeated at least three times for the validation of results.
Data was analyzed using a one-way analysis of variance
(ANOVA), followed by Student–Newman–Keul’s or
Dunnett’s post-hoc test. A P value, p < 0.05 was consid-
ered to be statistically significant.
Results
TBHQ up regulated transcription factor Nrf2 in U87MG
glioma cells
To establish the role of transcription factor Nrf2 in
glioma cells, we employed an Nrf2 inducer, TBHQ. We
found that TBHQ treatment (30-120 μM) significantly
augmented the protein expression of Nrf2 in U87MG
cells (Figure 1A and B). A 6 h treatment with 30 μM of
TBHQ resulted in 133% ± 30 (p < 0.05 vs. vehicle) in-
crease in Nrf2 levels in U87MG cells in comparison to
vehicle treated cells (Figure 1B). Immunocytochemical
analysis reaffirmed the induction of Nrf2 upon TBHQ
treatment. Notably, the TBHQ treatment also resulted in
enhanced nuclear translocation of Nrf2 as evidenced by
increased colocalization of Nrf2 with the nuclear stain,
DAPI in comparison to control (Figure 1C). The expres-
sion of Heme oxygenase 1 (HO-1), one of the potential
downstream targets of Nrf2, was next analyzed. The re-
sults showed that U87MG cells constitutively express
the HO-1 protein (Figure 1D). Moreover, U87MG cells
treated with TBHQ exhibited a significant increase in
HO-1 expression (Figure 1D and E), suggesting TBHQ
mediated upregulation of Nrf2 transcriptional activity.
Given the role of redox mechanisms in tumor cell prolif-
eration coupled with the role of Nrf2 in cellular antioxi-
dant defense mechanisms [23], we first questioned
whether Nrf2 induction in glioma cells modulates cellu-
lar proliferation. To this end, the effect of TBHQ on the
Figure 1 TBHQ and Nrf2 upregulation. U87MG cells were treated with either vehicle or TBHQ for 6 h and the induction of Nrf2 (MW: ~102 kDa)
was quantified using (A) western blotting followed by (B) densitometry analysis. The immunocytochemistry analysis followed by (C) confocal imaging
further confirmed induction and nuclear translocation of Nrf2 in glioma cells by TBHQ (scale bar = 50 μm). TBHQ treatment of glioma cells also
resulted in the induction of HO-1 (MW : ~31 kDa), one of the Nrf2 regulated molecular targets, as evidenced by (D) western blotting followed
by (E) densitometry analysis. Densitometry is expressed as the mean ± SEM from three independent trials and data were analyzed using
One-way ANOVA followed by Dunnett’s post-hoc test (* p < 0.05, ** p < 0.01, *** p < 0.001 vs. vehicle-treated cultures).
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incorporation assay. TBHQ treatment augmented BrdU
incorporation in glioma cells by 17.5% (p < 0.01 vs. ve-
hicle) as compared to vehicle treatment (Figure 2A).
Moreover, the MTT proliferation assay further validated
the increase in glioma cell proliferation by TBHQ
(Figure 2B) and demonstrated 11.5 and 14.7% increase
in proliferation upon 30 and 60 μM of TBHQ treat-
ment, respectively.
TBHQ attenuated Carmustine induced cytotoxicity in
glioma cells
To delineate the role of Nrf2 in chemoresistance to
Carmustine, we pre-treated U87MG cells with TBHQ
for 6 h and the cytotoxic response to Carmustine was
studied. TBHQ pre-treated U87MG cells exhibited sig-
nificantly lower cytotoxicity to Carmustine in compari-
son to vehicle treated cells (Figure 3A). Along theselines, Carmustine (50 μg/ ml) induced 85.26 ± 0.8761%
cytotoxicity in U87MG cells and upon TBHQ pre-
treatment the Carmustine mediated cytotoxicity was re-
duced to 44.64 ± 2.325% (p < 0.001 vs. Carmustine treat-
ment alone) (Figure 3A). Moreover, the 6 h pre-treatment
with TBHQ did not significantly increase the proliferation
of U87MG cells in comparison to vehicle treated controls
(n = 8; data not shown) suggesting the role of Nrf2 medi-
ated antioxidant signaling independent of proliferation in
attenuating Carmustine mediated cytotoxicity. Fur-
thermore, similar results were obtained in another hu-
man malignant glioma cell line, U118 (Additional file 1:
Figure S1), reaffirming the role of Nrf2 in Carmustine me-
diated cytotoxic effects in glioma. The cellular viability
studies were further verified using flow cytometry analysis
(Figure 3B), which demonstrated a significant reduction in
Carmustine mediated cytotoxicity upon TBHQ treatment
(Figure 3C).
Figure 2 TBHQ and glioma cell proliferation. U87MG cells were treated with either vehicle or TBHQ for 24 h and the cellular proliferation was
assessed using (A) BrdU incorporation assay and (B) MTT assay as described in Methods. Data are representative of at least three independent
trials (n = 3/trial) and are expressed as mean ± SEM. ** p < 0.01, *** p < 0.001 vs. vehicle-treated cultures.
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to Carmustine mediated cytotoxicity
To further establish the role of Nrf2 in Carmustine re-
sistance, we performed genetic overexpression of Nrf2 in
U87MG cells using lentiviral particles. The induction of
Nrf2 by lenti viral particles was confirmed by western
blotting analysis (Figure 4A). Cells transduced with lenti-
viral particles containing Red Fluorescent Protein (RFP)
served as the experimental control (Figure 4D; left
panel). In addition, a TransAM ELISA was performed to
validate the DNA binding activity of Nrf2 upon genetic
overexpression. As shown in Figure 4B, a 103.7% in-
crease in DNA binding activity of Nrf2 was found in the
nuclear extracts derived from Nrf2 overexpressed cells
in comparison to RFP overexpressed cells. In addition,
genetic over expression of Nrf2 was associated with the
induction HO-1 further confirming Nrf2 mediated regu-
lation of HO-1 in U87MG glioma cells (Figure 4C).
More importantly, Nrf2 overexpressed cells exhibited
significantly lower cytotoxicity to Carmustine in com-
parison to RFP over expressed cells (Figure 4D and E).
To further explore the role of antioxidant mechanisms
in tumor cell resistance to Carmustine, we studied the
role of antioxidants such as glutathione and N-acetyl
cysteine in Carmustine mediated cytotoxic effects. Inter-
estingly, we found that both glutathione and N-acetyl
cysteine significantly attenuated Carmustine mediated
cytotoxicity in U87MG cells. Carmustine treatment alone
induced 39.4% cytotoxicity in U87MG cells, whereas co
treatment of Carmustine with glutathione or N-acetyl
cysteine the induction of cytotoxicity was reduced to 6.01
and 4.87% respectively (Figure 5A and B).Discussion
Though surgical resection is one of the prime treatment
options for malignant glioma, the complete surgical
removal of the tumor is often a challenge owing to the
infiltrative nature of glioma. Thus, the treatment strategy
frequently demands chemotherapeutic approaches for
improved patient outcomes and a better understanding
of the underlying mechanisms of chemoresistance is
therefore critical. The intracerebral delivery of Carmustine
using Carmustine wafers is found to be very well tolerated
in patients and it allows drug release in a constant manner
with minimal systemic toxicity [24]. However, Carmustine
failed to substantially prolong median survival of GBM pa-
tients. The reason for this unsatisfactory clinical outcome
remains unclear but may involve intrinsic/acquired che-
moresistance of the tumor cells. To this end, variations in
multidrug resistance genes [25-27] and DNA repair activ-
ity [28] have been demonstrated to play roles in glioma
resistance to Carmustine. Although, several studies have
shown that a deficiency of DNA repair enzyme, O6-
methylguanine methyl-DNA transferase (MGMT) can
increase the sensitivity of glioma to Carmustine [29-31],
many tumors with low levels of MGMT are nevertheless
chemoresistant [32,33], suggesting the involvement of
other unknown mechanisms of chemoresistance.
Though Nrf2 has been implicated in chemoresistance
to 5-fluorouracil, carboplatin, cisplatin and temozolo-
mide [20,34-37], the role of Nrf2 in glioma resistance to
Carmustine remained largely uncharacterized. Herein,
we report for the first time that both pharmacological
and genetic upregulation of Nrf2 in U87MG grade IV ma-
lignant glioma cells significantly attenuate Carmustine
Figure 3 TBHQ and resistance to Carmustine. U87MG cells were treated with either vehicle or TBHQ (30 μM) for 6 h. After respective
treatment, the media were removed, cells were replenished with media containing either vehicle or Carmustine at indicated concentrations and
incubated for 18 h. The cell viability was measured using (A) MTT reduction assay and (B) flow cytometry analysis. Data from MTT Assay are
representative of three independent experiments and are expressed as mean ± SEM. ** p < 0.01, *** p < 0.001 vs. vehicle treated cells. For flow
cytometry analysis, the cells after treatments were collected and stained with 7-AAD (y-axis) a marker of cell death and Annexin V (x –axis), a
marker of early apoptotic cell death. The percentages of viable cells (C) which are both Annexin V/7-AAD negative are shown. Data are
representative of two independent experiments and are expressed as mean ± SEM. *** p < 0.001 vs. Carmustine alone treated cells.
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implications, given that tumor cells often exhibit elevated
metabolic rate and may have augmented Nrf2 level as a
result of tumor cell adaptation to high metabolic demand.
Along these lines, a number of malignant tumors such as
lung, ovarian, colon, breast and pancreatic cancer, exhibit
an increased transcriptional activity of Nrf2 [38-43]. Our
findings also demonstrate that as a consequence of
enhanced Nrf2 expression, glioma cells could acquire aug-
mented cellular proliferation. In addition, a recent study
also identified a role of Nrf2 in promoting tumor angio-
genesis through the HIF-1 α/ VEGF pathways [16].
Altogether, strategies to pharmacologically attenuate the
Nrf2 levels and/or activity may reduce glioma growth and
resistance to Carmustine.
Keap1, a BTB-Kelch protein, is regarded as the princi-
pal and negative regulator of Nrf2 and several protein
kinase pathways, including mitogen-activated protein
kinase and protein kinase C, have been implicated intransducing signals that control Nrf2 dependent gene
expression [44,45]. Promoter methylation of KEAP1
gene is found in malignant glioma [46] and a strong in-
verse correlation is discovered between methylation
levels and KEAP1 mRNA transcript in tumor tissue [46]
suggesting a reduced expression of KEAP1 in glioma. In
line with this, both U87MG and T98G glioma cells (data
not shown) express basal protein expression of Nrf2.
Nrf2 is believed to exert its transcriptional function by
forming heterodimers with small Maf (v-maf musculo-
aponeurotic fibrosarcoma oncogene family) proteins,
and binding to ARE-containing gene promoters [14].
Our studies demonstrate that Nrf2 regulates the expres-
sion of HO-1 in glioma cells. HO-1 is a rate-limiting en-
zyme that catalyzes heme degradation in which oxidative
cleavage of the porphyrin ring results in the generation
of biliverdin (antioxidant), carbon monoxide (anti apop-
totic), and free iron [47,48]. HO-1 belongs to heat shock
protein family and its expression is triggered by various
Figure 5 Antioxidants and Carmustine cytotoxicity. U87MG cells were treated with Carmustine (40 μg/ml) for 18 h in the presence of either
(A) glutathione (GSH;5 mM) or (B) N-acetyl cysteine (NAC; 5 mM) and cellular viability was quantified using MTT assay. Data are representative of
at least three independent trials (n = 3/trial) and are expressed as mean ± SEM. *** p < 0.001 vs. Carmustine alone treated cultures.
Figure 4 Nrf2 and resistance to Carmustine. U87MG cells were stably transduced with the Precision LentiORF lentiviral particles to accomplish
Nrf2 (MW: ~102 kDa) overexpression evidenced by (A) western blotting. The genetic over expression of Nrf2 resulted in increased Nrf2 transcriptional
activity as assessed by (B) TransAM Elisa and augmented expression of HO-1 as assessed by western blotting (C). The confocal image (D) illustrates
U87MG cells overexpressed with Red Fluoresent protein (RFP) that served as experimental control (scale bar = 200 μm). The U87MG cells stably over
expressing either RFP or Nrf2 were subjected to ether vehicle or Carmustine treatment for 18 h and the cellular viability was assessed by (E) MTT
reduction assay and the Figure 4D demonstrates the cellular morphology of cells upon Carmustine treatment using bright field microscopy (Scale
bar =200 μm). Data are representative of at least three independent trials (n = 3/trial) and are expressed as mean ± SEM. ** p < 0.01, *** p < 0.001 vs.
vehicle-treated cultures.
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hypoxia and heavy metals [49,50]. Owing to the antioxi-
dant and cytoprotective nature of the enzymatic products
of HO-1, elevated HO-1 expression due to deregulated
Nrf2 signaling could protect tumor cells from oxidative
stress-related injury and function as a key component
of tumor cell adaptation to oxidative stress induced
by chemotherapeutic agents [51]. Therefore, further
characterization of Nrf2-HO-1 signaling is highly
warranted and may lead to the development of novel
therapeutic strategies for malignant glioma.
Apart from heme oxygenase 1 (HO-1), the best-
characterized Nrf2 downstream genes include gluta-
thione biosynthesizing enzymes such as glutathione
S-transferases A1 and glutamate-cysteine ligase. For
instance, Nrf2 knockout mice exhibit reduced expres-
sion of both detoxification enzymes and antioxidants
[52,53]. Oxidative stress is widely implicated in the
etiology of cancer and results from an imbalance in
the production of Reactive Oxygen Species (ROS) and
cell’s own antioxidant defenses. ROS are found ele-
vated during cancer and have been shown to activate
signaling pathways involved in cellular proliferation
and migration [23]. Carmustine-mediated malignant
glioma cell death was significantly attenuated by co-
treatment with antioxidants such as N-acetyl-L-cysteine
and glutathione, suggesting the prominent role of oxi-
dative stress mechanisms in conferring Carmustine-
mediated cytotoxicity. Many chemotherapeutic agents
produce cytotoxic effects via generation of ROS and/or
electrophilic actions, which lead to oxidative stress
[54-56]. To this end, Carmustine is known to inhibit
glutathione reductase [57,58], an integral component
of the antioxidant defense mechanisms. Therefore,
antitumor agents may also activate Nrf2 antioxidant
signaling in tumor cells in a ROS-dependent manner,
leading to the development of acquired chemoresis-
tance. Though antioxidant vitamins such as retinoids,
vitamin C, vitamin E and carotenoids have been ex-
tensively investigated in cancer prevention, the role
of these vitamins in attenuating the efficacy of che-
motherapeutic agents needs to be elucidated. In
addition, Nrf2 is also known to regulate the expres-
sion of cysteine/glutamate exchange transporter, xCT
that maintains extracellular glutamate levels [59].
Therefore, future studies are warranted to demon-
strate the role of Nrf2 in regulating xCT expression
and/or activity in glioma, as augmented levels of glu-
tamate may facilitate tumor growth by eliciting neur-
onal damage. Altogether, Nrf2 may represent a very
effective and potent therapeutic target for glioma and
pharmacological inhibitors of Nrf2 may serve as a
useful adjunct to Carmustine for the treatment of
malignant glioma.Conclusion
In conclusion, we have demonstrated a novel role of
Nrf2 in malignant glioma cell resistance to Carmustine.
Altogether, the data suggest that antioxidant transcrip-
tion factor Nrf2 might be a potent and viable molecular
target for the treatment of malignant glioma.
Additional file
Additional file 1: Figure S1. Human U118 malignant glioma cells
(kindly donated by Dr. Raghavan Raju, Allied Health Sciences, Georgia
Regents University) were cultured (3 × 104 cells/well in 24 well plate) in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 5%
fetal bovine serum, 5% bovine growth serum, and antibiotics in a 37°C
humidified incubator at 5% CO2 and were treated with either vehicle or
TBHQ (30 μM) for 6 h. After respective treatment, the media were
removed; cells were replenished with media containing either vehicle or
Carmustine at indicated concentrations and incubated for 18 h. The cell
viability was measured using MTT reduction assay. Data from MTT Assay
are representative of three independent experiments and are expressed
as mean ± SEM. *** p < 0.001 vs. vehicle treated cells.
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